Literature DB >> 24306063

Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei.

P Berkovic1, L van de Voorde, G De Meerleer, L Delrue, B Speleers, S Van Belle, K Vandecasteele.   

Abstract

BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by mucinous peritoneal disease arising from disseminated peritoneal adenomucinosis. Primary treatment involves a combination of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). There is no consensus on the proper treatment of recurrent PMP. In selected patients, repeated cytoreductive surgery with or without HIPEC might improve outcome. However, every repeated debulking procedure becomes less effective with increased morbidity. CASE REPORT: We present a case of a patient with intestinal obstruction caused by recurrent pseudomyxoma peritonei. We treated the patient with whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT) to a total dose of 33 Gy, delivered in 22 daily fractions. The treatment was well tolerated and resulted in resolution of the obstruction for a period of 24 months.
CONCLUSION: To the best of our knowledge, we present the first case report showing the possibility of resolving intestinal obstruction with WAPRT in a patient with recurrent PMP. It is our opinion that WAPRT delivered by IMAT, in analogy with ovarian cancer, should be considered as a palliative treatment option in managing patients with recurrent PMP especially in case of obstruction.

Entities:  

Mesh:

Year:  2013        PMID: 24306063     DOI: 10.1007/s00066-013-0470-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  22 in total

1.  Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience.

Authors:  Wim Duthoy; Werner De Gersem; Koen Vergote; Marc Coghe; Tom Boterberg; Yves De Deene; Carlos De Wagter; Simon Van Belle; Wilfried De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-15       Impact factor: 7.038

2.  Pseudomyxoma peritonei treated by radiotherapy.

Authors:  S el Sayed
Journal:  Clin Oncol (R Coll Radiol)       Date:  1990-03       Impact factor: 4.126

3.  Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis.

Authors:  B M Ronnett; H Yan; R J Kurman; B M Shmookler; L Wu; P H Sugarbaker
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

Review 4.  Epithelial ovarian cancer: the role of radiotherapy.

Authors:  A J Dembo
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

Review 5.  Pseudomyxoma peritonei.

Authors:  R M Smeenk; V J Verwaal; F A N Zoetmulder
Journal:  Cancer Treat Rev       Date:  2006-12-19       Impact factor: 12.111

6.  Risk factors related to interfractional variation in whole pelvic irradiation for locally advanced pelvic malignancies.

Authors:  W S Yoon; D S Yang; J A Lee; S Lee; Y J Park; C Y Kim
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

7.  Pseudomyxoma peritonei: more questions than answers.

Authors:  Eric K Nakakura
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

Review 8.  Pseudomyxoma peritonei.

Authors:  Robert M Smeenk; Sjoerd C Bruin; Marie-Louise F van Velthuysen; Victor J Verwaal
Journal:  Curr Probl Surg       Date:  2008-08       Impact factor: 1.909

9.  Helical tomotherapy as a new treatment technique for whole abdominal irradiation.

Authors:  Nathalie Rochet; Florian Sterzing; Alexandra Jensen; Julien Dinkel; Klaus Herfarth; Kai Schubert; Michael Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus; Wolfgang Harms
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

10.  Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.

Authors:  Tristan D Yan; Lana Bijelic; Paul H Sugarbaker
Journal:  Ann Surg Oncol       Date:  2007-06-01       Impact factor: 5.344

View more
  3 in total

1.  Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.

Authors:  Nathalie Rochet; Katja Lindel; Sonja Katayama; Kai Schubert; Klaus Herfarth; Andreas Schneeweiss; Christoph Sohn; Wolfgang Harms; Juergen Debus
Journal:  Strahlenther Onkol       Date:  2015-03-19       Impact factor: 3.621

Review 2.  Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  Orphanet J Rare Dis       Date:  2014-05-05       Impact factor: 4.123

3.  Palliative Radiation Therapy for Symptom Control in an Advanced Case of Pseudomyxoma Peritonei.

Authors:  Clare McGrath; Kelly Linden; Pamela Hube; Anna Adamiak; Kristopher Dennis
Journal:  Cureus       Date:  2017-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.